Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 8, 2012 - Issue 10
Submit an article Journal homepage
1,029
Views
25
CrossRef citations to date
0
Altmetric
Special Focus Review

Recombinant allergens

The present and the future

Marek Jutel Department of Clinical Immunology; Wroclaw Medical University; Wroclaw, PolandCorrespondence[email protected]
,
Katarzyna Solarewicz-Madejek Department of Clinical Immunology; Wroclaw Medical University; Wroclaw, Poland
&
Sylwia Smolinska Department of Clinical Immunology; Wroclaw Medical University; Wroclaw, Poland
Pages 1534-1543 | Received 28 Jun 2012, Accepted 03 Sep 2012, Published online: 01 Oct 2012
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Peptide immunotherapy for allergic diseases
Source: Wiley
The safety and efficacy of ALLERVAX CAT in cat allergic patients.
Source: Elsevier BV
Vaccination with genetically engineered allergens prevents progression of allergic disease
Source: Proceedings of the National Academy of Sciences
Mechanisms of allergen-specific desensitization
Source: Elsevier
Comparisons between rBet v 1 with rBet v 1 wild-types
Source: Wiley
Hypoallergen treatment in a mouse model for cat allergy
Source: Wiley
A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity
Source: The American Association of Immunologists
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.
Source: Elsevier BV
Peptide and recombinant immunotherapy.
Source: Elsevier BV
Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
Source: Wiley
Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy.
Source: Wiley-Blackwell
IgE-binding epitopes
Source: Wiley
Application of multiplexed immunoglobulin E determination on a chip in component-resolved diagnostics in allergy.
Source: Wiley
Immunotherapy with peptides
Source: Wiley
Component resolved testing for allergic sensitization.
Source: Springer Science and Business Media LLC
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis
Source: Elsevier BV
Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.
Source: Wiley
Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
Source: Springer Nature
Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases.
Source: Rockefeller University Press
Prevention of new sensitizations
Source: Wiley
History of allergen-specific immunotherapy
Source: Wiley
Studies on allergoids from naturally occurring allergens III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps
Source: Elsevier BV
Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view.
Source: Wiley
CRD and CRIT
Source: Wiley
Different allergenic activity of grass pollen allergens revealed by skin testing.
Source: Wiley
Recombinant allergen fragments as candidate preparations for allergen immunotherapy
Source: Elsevier BV
Allergen-specific immunotherapy with recombinant grass pollen allergens.
Source: Elsevier BV
Immunological mechanisms of allergen-specific immunotherapy
Source: Wiley
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.
Source: Wiley
A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.
Source: Elsevier BV
Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome
Source: Elsevier BV
S2k-Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), des Ärzteverbandes Deutscher Allergologen (AeDA), der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI), der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI), der Deutschen Dermatologischen Gesellschaft (DDG), der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC), der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ), der Gesellschaft für Pädiatrische Pneumologie (GPP), der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), des Deutschen Berufsverbandes der HNO-Ärzte (BV-HNO), des Berufsverbandes der Kinder- und Jugendärzte (BVKJ), des Bundesverbandes der Pneumologen (BDP) und des Berufsverbandes der Deutschen Dermatologen (BVDD)
Source: Springer Science and Business Media LLC
Recombinant allergen-based immunotherapy
Source: Wiley
Recombinant allergens: What does the future hold?
Source: Elsevier BV
Standardized allergen extracts: past, present and future
Source: Informa UK Limited
Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT)
Source: Elsevier BV
Treatment of cat allergy with T-cell reactive peptides.
Source: American Thoracic Society
Cloning and expression of DNA coding for the major house dust mite allergen Der p 1 in Escherichia coli.
Source: S. Karger AG
Allergen cross‐reactivity between house‐dust mites and other invertebrates
Source: Wiley
Future forms of immunotherapy
Source: Elsevier BV

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.